Biodesix, Inc. filings document the public reporting of a Nasdaq-listed diagnostics company with common stock trading under BDSX. The company’s 8-K reports disclose operating and financial results for its Diagnostic Testing and Development Services activities, including revenue trends, gross margin, guidance, and related press-release exhibits.
Proxy materials cover annual meeting proposals, board and governance matters, and stockholder voting. Other material-event filings document capital-structure and security-holder matters, including the completed one-for-twenty reverse stock split, common stock listing details, Nasdaq minimum bid price compliance, and amendments to the company’s charter.
Biodesix, Inc. and its Chief Commercial Officer, Kieran O’Kane, agreed on November 2, 2026, that his employment would end effective that date. O’Kane will be eligible for separation benefits under his existing Executive Severance and Change in Control Agreement based on a qualifying termination under its terms.
BIODESIX INC (BDSX) reported third-quarter 2026 revenue of $24.041 million, compared with $21.768 million a year earlier; nine-month revenue was $76.457 million versus $59.744 million. Diagnostic Tests revenue was $23.055 million, compared with $19.835 million, while Development Services revenue was $0.986 million versus $1.933 million. Net loss was $8.032 million for the quarter and $23.098 million for nine months, compared with $8.716 million and $31.285 million, respectively.
Operating cash use was $18.933 million for the nine months, compared with $24.049 million, and cash and cash equivalents were $28.409 million as of September 30, 2026. Under its 2024 ATM Program, Biodesix raised approximately $30.4 million gross and $29.5 million net from 2,460,441 shares at a weighted-average price of $12.38; up to $12.2 million of capacity remained as of September 30, 2026.
The Perceptive Term Loan Facility had $50.0 million in principal outstanding as of September 30, 2026, with a stated interest rate of approximately 12.92%. The Sixth Amendment extended its maturity to November 21, 2028, with an interest-only period through that date. Biodesix reported compliance with all restrictive and financial covenants as of September 30, 2026.
Biodesix (BDSX) reported third-quarter 2026 revenue of $24.0 million, up 10% year over year; Diagnostic Testing revenue rose 16% and test volumes rose 24% to 19,400. Gross margin was 81%, flat year over year. Net loss was $8.0 million, an 8% improvement, and Adjusted EBITDA loss was $3.9 million, a 16% improvement.
Development Services revenue was $1.0 million versus $1.9 million a year earlier, reflecting project completion and revenue-recognition timing. CEO Scott Hutton said growth was below expectations, citing fewer sales representatives than planned, seasonality in primary care and delays in external customer dependencies. Cash and cash equivalents were $28.4 million, down $1.6 million from June 30, 2026; the change included $6.3 million of net proceeds from the at-the-market program.
Biodesix expects 2026 revenue of $101 million to $103 million, with the midpoint representing approximately 15% growth over 2025, and expects gross margins of approximately 80%. A radiomics-based lung nodule test developed with Vanderbilt University and Vanderbilt Health is anticipated to be commercially available in 2028.
Biodesix Inc. chairman and director John Patience converted 1,360 restricted stock units (RSUs) into 1,360 common shares on September 30, 2026. Each RSU represents a contingent right to receive one common share. The RSUs vest in four substantially equal installments on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, generally subject to continued service.
Biodesix Inc. insider Jack W. Schuler, a ten percent owner and emeritus director, purchased 15,000 shares of common stock on August 12, 2026 at a weighted average price of $24.4661 per share, with trade prices ranging from $24.00 to $24.50. The shares were acquired indirectly through the Jack W. Schuler Living Trust, which now holds 555,810 shares. A separate indirect holding of 1,800,000 shares is reported for the Jack W. Schuler 2026 GRAT, for which Schuler is also sole trustee.
Biodesix Inc. insider Jack W. Schuler, a more-than-10% shareholder and emeritus director, reported two open-market purchases of common stock through the Jack W. Schuler Living Trust. On August 11, 2026, the trust purchased 13,700 shares at a weighted average price of $24.0081 per share, in multiple trades between $23.965 and $24.32. On August 10, 2026, it purchased 13,900 shares at a weighted average price of $24.2467 per share, in trades between $23.89 and $24.50. The filing also reports an indirect holding of 1,800,000 shares of common stock held by the Jack W. Schuler 2026 GRAT, for which Schuler is sole trustee. Reported amounts reflect exempt transfers between the Living Trust and related GRATs under Rule 16a-13, and the transactions were not executed under a Rule 10b5-1 trading plan.
Biodesix, Inc. reported Q2 2026 revenue of $26.9 million, up from $20.0 million a year earlier, with first‑half 2026 revenue of $52.4 million versus $38.0 million. Diagnostic Tests generated $25.3 million in Q2 and $47.6 million year‑to‑date, while Development Services contributed $1.5 million and $4.8 million.
Loss from operations narrowed to $5.4 million in Q2 2026 from $9.7 million, and net loss improved to $7.3 million from $11.5 million; first‑half net loss was $15.1 million versus $22.6 million. Net loss per share was $0.71 in Q2 and $1.51 for the first half, compared with $1.56 and $3.08.
Cash, cash equivalents, and restricted cash were $30.1 million at June 30, 2026, up from $20.8 million a year earlier, after $11.7 million of operating cash use and $23.1 million of net financing inflows in the first half. The company carries a $50.0 million Perceptive Term Loan Facility, interest‑only through November 21, 2028, and reported total liabilities of $86.2 million and positive stockholders’ equity of $9.1 million.
Biodesix, Inc. reported second-quarter 2026 results with total revenue of $26.9 million, a 34% year-over-year increase. Diagnostic Testing revenue was $25.4 million, up 42%, driven by 20,900 tests, a 38% volume increase and higher average revenue per test. Development Services revenue was $1.5 million, reflecting project timing.
Gross margin reached 82%, a 200-basis-point improvement. Operating expenses excluding direct costs were $27.4 million, up 7%. Net loss narrowed to $7.3 million, a 37% improvement, and Adjusted EBITDA loss improved to $3.2 million, a 56% improvement. Cash and cash equivalents were $30.0 million. Total assets were $95.3 million and stockholders’ equity improved to $9.1 million, up from a deficit at year-end 2025, while long-term notes payable were $46.8 million. Full-year 2026 revenue guidance remains $108–114 million, with the midpoint implying about 25% growth and maintaining gross margin of roughly 80% while progressing toward Adjusted EBITDA profitability.
Biodesix Inc. director and chairman John Patience reported a routine equity compensation transaction involving restricted stock units (RSUs) that converted into common shares. On June 30, 2026, he exercised 1,361 RSUs, receiving 1,361 shares of common stock, increasing his direct common stock holdings to 25,383 shares.
Following the transaction, he also directly holds 2,721 RSUs, each representing a contingent right to one share of common stock. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to his continued service with Biodesix. The filing also lists indirect holdings of common stock held by his spouse, the John Patience Living Trust dated July 23, 1993, and Patience Enterprises LP.
Biodesix, Inc. Schedule 13G shows Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of 525,241 shares of Biodesix common stock. The filing states this equals 5.1% of the class, based on 10,355,809 shares outstanding as of May 20, 2026.
The filing attributes the shares to the Master Fund and lists related entities and Guy Levy with shared voting and dispositive power over the 525,241 shares; the filing includes a standard disclaimer that affiliated entities and Mr. Levy disclaim beneficial ownership except for Section 13(d) purposes.